Lava Therapeutics creates and develops next generation γδ T-cell engaging bispecific antibodies for the treatment of cancer. Our first-in-class immuno-oncology approach activates γδ T cells in a tumor target dependent manner. The company’s proprietary γδ TCR-bispecific antibody platform originates from cutting-edge research at the VU University Medical Center and Cancer Center Amsterdam. The objective of Lava Therapeutics B.V is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells. We are backed by strong venture investors Versant Ventures, Gilde Healthcare and Merck Research Labs Ventures.• Closed collaboration with Janssen Pharmaceuticals • Closed a $83 million Series C investment with strong new investors • Navigated regulatory challenges to start two clinical trials• Established Corporate mission, vision, and strategic plan. • Closed IPO raising over $100 million • Closed collaboration with Seagen securing $50 million upfront, $650 million in milestones, and strong royalty rates.

Sesen is a NASDAQ listed biologics oncology company focused on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs). Lead product in Phase 3 clinical trial in the U.S. and Canada for the treatment of high-grade non-muscle invasive bladder cancer. Proxinium is being developed for late stage squamous cell carcinoma of the head and neck, with a Phase 1/2a clinical trial in combination with a checkpoint inhibitor planned to initiate at an appropriate time.• Managed acquisition integration. Established mission, strategy, team, and infrastructure to integrate and reinvigorate business.• Developed and executed a clear strategy, streamlined cost structure, investmented in people and products, and secured global partnerships.• Raised $70 million in 12 months from high quality investors, leveraging US banker, research analyst and industry relationships.• Built clinical and regulatory teams with key strategic hires; secured FDA Fast Track designation; and, established strong KOL support base for lead program.• Drove full enrollment in Phase 3 registration trial and presentation of initial response data.• Utilized strong industry contacts to lead all business development partnering and licensing interactions, including execution of immune-oncology checkpoint partnership with the U.S. National Cancer Institute and AstraZeneca.• Managed complicated manufacturing technology transfer project including scale up, CMC planning, and accelerated timelines.• Initiated commercial launch activities including payer panels, KOL advocacy, pricing analysis, patient profiling and market access.

Private Oncology firm developing targeted protein therapies.• Led business from private ownership through acquisition by Eleven Bio. Established corporate strategy, financial operations, recruited and hired leadership team and key personnel, and managed FDA negotiations.• Developed strategic plan for organization. Managed submittals and negotiations with the FDA through approval of Registration Phase 3 clinical trial.• Negotiated with FDA for approval of innovative Phase 3 registration trial• Managed pre-clinical development or earlier stage pipeline, including filing if IND.• Recruited Board of Directors and implemented corporate governance and reporting structure in preparation for IPO.• Developed significant KOL support system, including industry leaders in oncology and immunology.• Built investment case for relatively unknown firm eventually securing support of world-class investors and investment banks.• Led IPO process, including securing underwriters (Leerink & Cowen), filing S-1 and building investor book. • Sold Company to Eleven Bio.

• Recruited to turn around struggling Merchant Banking Group.• Developed corporate strategy that leveraged unique assets and realigned staff to implement.• Utilized Investment Banking and Investor relationships to expanded Capital Markets practice. Completed first ever capital raise in first year and completed 5 transactions second year.• Successfully developed group to operating cash flow positive within 2 year. • Integrated international relationships with M&A franchise to secure and close global transactions, including Samsung Biosimilar transaction in Korea and Eddingpharm in China.• Balanced mix of engagements from advisory (including M&A and licensing) to capital raising.• Raised over $100 million and completed high quality public and private capital transactions.• Managed principal investing through the Merchant Bank• Acting President for Viventia Bio for one year; recruited from firm to CEO role with Viventia Bio.

• Responsible for start-up of Health Care Investment Banking Practice, building to team of 5 bankers, 2 analysts and 2 dedicated sales/traders.• Successfully developed Practice to strong positive contributor in 2 years, closing 8 transactions and raising $325 million for clients.• Utilized industry relationships to complete 3 strategic M&A and partnering transactions. • Additional responsibility for developing maturity of Capital Markets throughout the firm, establishing the group as a prominent member of the Wall Street Healthcare landscape.• Recruited to Burrill & Co.

• Launched Life Sciences Investment Banking effort. • Sourced eight high quality engagements in first year based on industry relationships, including US and European transactions.• Strong focus on high margin advisory business, and lead-managed capital raising, including industry leading Biovex transaction.• Established and led our international health care advisory practice growth, including engagements in China, Europe and Australia, resulting in 12 closed transactions and record revenue.

Venture backed portfolio investment of JP Morgan/H&Q. ISP focused on residential and business connectivity and data services. Implemented turnaround plan, reducing costs, refocusing of high margin business lines and setting clear strategy. Successfully achieved profitability for first time in 5 years.

Executive Vice President, Executive Office• Recruited to the Executive Office as the Assistant to the CEO, Dan Case.• Responsible for managing key relationships with Private Equity, venture funds and top-tier operators.• Executing high profile advisory transactions for the firm nationally and internationally.• Managed principal investing as well as review and transition of internal venture portfolio.

Principal, Investment Banking • Senior Banker on over two dozen strategic advisory assignments including buy and sell side engagements and strategic advisory assignments.• Over three dozen IPOs and capital raisings completed. • Recruited, trained, staffed and supervised junior bankers.

Investment Banking / Venture Capital